AYTU BIOPHARMA, INC Increase (Decrease) in Accounts Payable
AYTU BIOPHARMA, INC (AYTU) reported Increase (Decrease) in Accounts Payable of -$2.32 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-22.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-09-22
- AYTU BIOPHARMA, INC increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$1.93M.
- AYTU BIOPHARMA, INC increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$1.04M, a 362.56% decline year-over-year.
- AYTU BIOPHARMA, INC increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$1.08M.
- AYTU BIOPHARMA, INC increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $1.74M, a 44.61% decline year-over-year.
- AYTU BIOPHARMA, INC increase (decrease) in accounts payable for fiscal 2026 was -$2.32M, a 907.32% decline from fiscal 2025.
- AYTU BIOPHARMA, INC increase (decrease) in accounts payable for fiscal 2025 was $287.00K.
- AYTU BIOPHARMA, INC increase (decrease) in accounts payable for fiscal 2024 was -$2.08M, a 187.08% decline from fiscal 2023.
- AYTU BIOPHARMA, INC increase (decrease) in accounts payable for fiscal 2023 was $2.38M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 6 month as first filed | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 9 month as first filed | Increase (Decrease) in Accounts Payable 12 month | Increase (Decrease) in Accounts Payable 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22 | -$2.98M derived: sum of 2 quarters · filed 2026-09-22 | -$4.06M derived: sum of 3 quarters · filed 2026-09-22 | -$2.32M 10-K · filed 2026-09-22 | |||
| 2026-03-31 | -$1.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-13 | -$2.13M derived: sum of 2 quarters · filed 2026-05-13 | -$387.00K 10-Q · filed 2026-05-13 | -$1.83M derived: sum of 4 quarters · filed 2026-09-22 | |||
| 2025-12-31 | -$1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-03 | $658.00K 10-Q · filed 2026-02-03 | -$782.00K derived: sum of 3 quarters · filed 2026-09-22 | -$384.00K derived: sum of 4 quarters · filed 2026-09-22 | |||
| 2025-09-30 | $1.74M 10-Q · filed 2025-11-13 | $301.00K derived: sum of 2 quarters · filed 2026-09-22 | $699.00K derived: sum of 3 quarters · filed 2026-09-22 | -$1.11M derived: sum of 4 quarters · filed 2026-09-22 | |||
| 2025-06-30 | -$1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22 | -$1.04M derived: sum of 2 quarters · filed 2026-09-22 | -$2.86M derived: sum of 3 quarters · filed 2026-09-22 | $287.00K 10-K · filed 2026-09-22 | |||
| 2025-03-31 | $398.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-13 | -$1.42M derived: sum of 2 quarters · filed 2026-05-13 | $1.73M 10-Q · filed 2026-05-13 | $1.86M derived: sum of 4 quarters · filed 2026-05-13 | |||
| 2024-12-31 | -$1.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-03 | $1.33M 10-Q · filed 2026-02-03 | $1.46M derived: sum of 3 quarters · filed 2026-02-03 | $2.31M derived: sum of 4 quarters · filed 2026-02-03 | |||
| 2024-09-30 | $3.14M 10-Q · filed 2025-11-13 | $3.28M derived: sum of 2 quarters · filed 2025-11-13 | $3.14M 10-Q · filed 2024-11-13 | $153.00K derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | $134.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23 | $986.00K derived: sum of 2 quarters · filed 2025-09-23 | -$2.99M derived: sum of 3 quarters · filed 2025-09-23 | -$2.08M 10-K · filed 2025-09-23 | -$2.88M 10-K · filed 2024-09-26 | ||
| 2024-03-31 | $852.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-14 | -$3.12M derived: sum of 2 quarters · filed 2025-05-14 | -$2.21M 10-Q · filed 2025-05-14 | -$2.94M 10-Q · filed 2024-05-15 | -$3.55M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | -$3.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-12 | -$3.06M 10-Q · filed 2025-02-12 | -$3.03M 10-Q · filed 2024-02-14 | -$4.40M derived: sum of 3 quarters · filed 2025-02-12 | $160.00K derived: sum of 4 quarters · filed 2025-02-12 | ||
| 2023-09-30 | $914.00K 10-Q · filed 2023-11-14 | -$422.00K derived: sum of 2 quarters · filed 2024-09-26 | $946.00K 10-Q · filed 2024-11-13 | -$289.00K derived: sum of 4 quarters · filed 2024-09-26 | |||
| 2023-06-30 | -$1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-26 | $3.22M derived: sum of 2 quarters · filed 2024-09-26 | -$1.20M derived: sum of 3 quarters · filed 2024-09-26 | $2.38M 10-K · filed 2024-09-26 | |||
| 2023-03-31 | $4.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | $133.00K derived: sum of 2 quarters · filed 2024-05-15 | $3.72M 10-Q · filed 2024-05-15 | $4.14M derived: sum of 4 quarters · filed 2024-05-15 | |||
| 2022-12-31 | -$4.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-14 | -$838.00K 10-Q · filed 2024-02-14 | -$420.00K derived: sum of 3 quarters · filed 2024-02-14 | -$5.21M derived: sum of 4 quarters · filed 2024-02-14 | |||
| 2022-09-30 | $3.59M 10-Q · filed 2023-11-14 | $4.00M derived: sum of 2 quarters · filed 2023-11-14 | -$787.00K derived: sum of 3 quarters · filed 2023-11-14 | $5.79M derived: sum of 4 quarters · filed 2023-11-14 | |||
| 2022-06-30 | $418.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-12 | -$4.37M derived: sum of 2 quarters · filed 2023-10-12 | $2.21M derived: sum of 3 quarters · filed 2023-10-12 | -$7.68M 10-K · filed 2023-10-12 | |||
| 2022-03-31 | -$4.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-11 | $1.79M derived: sum of 2 quarters · filed 2023-05-11 | -$8.10M 10-Q · filed 2023-05-11 | -$5.19M derived: sum of 4 quarters · filed 2023-05-11 | |||
| 2021-12-31 | $6.58M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2023-02-21 | -$3.31M 10-Q · filed 2023-02-21 | -$396.00K derived: sum of 3 quarters · filed 2023-02-21 | -$3.42M derived: sum of 4 quarters · filed 2023-02-21 | |||
| 2021-09-30 | -$9.89M 10-Q/A · filed 2023-02-21 | -$6.98M derived: sum of 2 quarters · filed 2023-02-21 | -$10.00M derived: sum of 3 quarters · filed 2023-02-21 | -$8.61M derived: sum of 4 quarters · filed 2023-02-21 | |||
| 2021-06-30 | $2.91M derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-27 | -$109.00K derived: sum of 2 quarters · filed 2022-09-27 | $1.27M derived: sum of 3 quarters · filed 2022-09-27 | -$3.25M 10-K · filed 2022-09-27 | |||
| 2021-03-31 | -$3.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-16 | -$1.64M derived: sum of 2 quarters · filed 2022-05-16 | -$6.16M 10-Q · filed 2022-05-16 | -$6.16M 10-Q · filed 2021-05-17 | -$2.62M derived: sum of 4 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $1.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-14 | -$3.14M 10-Q · filed 2022-02-14 | -$3.14M 10-Q · filed 2021-02-11 | $399.25K derived: sum of 3 quarters · filed 2022-02-14 | -$7.32M derived: sum of 4 quarters · filed 2022-02-14 | ||
| 2020-09-30 | -$4.52M 10-Q · filed 2021-11-15 | -$984.75K derived: sum of 2 quarters · filed 2021-11-15 | -$8.70M derived: sum of 3 quarters · filed 2021-11-15 | ||||
| 2020-06-30 | $3.54M derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-28 | -$4.18M derived: sum of 2 quarters · filed 2021-09-28 | -$1.38M 10-K · filed 2021-09-28 | ||||
| 2020-03-31 | -$7.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-05-17 | -$4.91M 10-Q · filed 2021-05-17 | |||||
| 2019-12-31 | $2.81M 10-Q · filed 2021-02-11 | ||||||
| 2016-03-31 | -$38.45K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-11 | $0.00 10-Q · filed 2016-05-11 | |||||
| 2015-12-31 | $38.45K 10-Q · filed 2016-02-11 | ||||||
| 2015-06-30 | $939.82K derived: 10-K 12 month − 10-Q 9 month · filed 2015-09-28 | $1.11M derived: sum of 2 quarters · filed 2016-05-11 | $509.94K derived: sum of 3 quarters · filed 2016-05-11 | $547.31K 10-K · filed 2015-09-28 | |||
| 2015-03-31 | $168.55K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-11 | -$429.88K derived: sum of 2 quarters · filed 2016-05-11 | -$392.51K 10-Q · filed 2016-05-11 | -$103.16K 10-Q · filed 2015-05-19 | -$553.54K derived: sum of 4 quarters · filed 2016-05-11 | ||
| 2014-12-31 | -$598.43K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-11 | -$561.06K 10-Q · filed 2016-02-11 | -$722.09K derived: sum of 3 quarters · filed 2016-02-11 | ||||
| 2014-09-30 | $37.38K 10-Q · filed 2015-11-06 | -$123.65K derived: sum of 2 quarters · filed 2015-11-06 | |||||
| 2014-06-30 | -$161.03K derived: 10-K 12 month − 10-Q 9 month · filed 2015-09-28 | $421.87K 10-K · filed 2015-09-28 | |||||
| 2014-03-31 | $582.90K 10-Q · filed 2015-05-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |